Prof. Dr. med. Albert Ludolph

Department of Neurology
University of Ulm


Research interests & methods focus

Amyotrophic lateral sclerosis, frontotemporal dementias, Huntington´s disease and other neurodegenerative diseases, toxic mechanisms of neurodegeneration, clinical trials and their methodology


Training

  • 1973 – 1979 Study of Medicine in Mainz and Göttingen, Germany

  • 1979 – 1984 Resident at the Department of Neurology and Psychiatry (University of Münster)

  • 1985 – 1989 Staff, Department of Neurology, University of Münster

  • 1990 – 1992 Staff Scientist, Center for Research on Occupational and Environmental Toxicology and the Department of Neurology, Portland (Oregon)

  • 1992 Staff, Department of Epileptology, University of Bonn


Academic positions & appointments

  • 1987 Habilitation, Faculty of Medicine, University of Münster, C2 Professor of Neurology

  • 1993 – 1996 C3 Prof. of Neurology, Vice Chairman, Department of Neurology, Humboldt University Berlin

  • 1996 – now C4 Professor of Neurology, Chair, Department of Neurology, University of Ulm

Awards & honors

  • 1984 – 1985 Stipend, Deutsche Forschungsgemeinschaft: Institute of Neurotoxicology, Albert Einstein College of Medicine, Bronx, New York

  • 2013 Honorary Member of the Mongolian Society of Neurology

  • 2015 Erb-Gedenkmünze of the German Society of Neurology (DGN)

  • 2017 Eva Luise Köhler Prize

  • 2018 Honorary Doctor of the Medical Faculty University of Frankfurt

  • 2019 Prize for collaboration with industry, University of Ulm

  • 2019 Erb-Duchenne prize of the German Society for Muscle Diseases (DGM)


Third party funding (selected 3 most important)

  • 2012 – 2015 BMBF – German Network for Motor Neuron Diseases

  • 2014 – 2017 DFG LU336/16 – LIPCAL-ALS

  • 2018 – now EU H2020-SC1-PM-08-2017-Project 755094 – TUDCA-ALS


Academic responsibilities

Chair, Academic Neuroscience Center, University of Ulm (2003 - 2017) / Chair, ALS Panel of the EFNS and EAN (2007 – 2019) / Chair, World Federation of Neurology, ALS Research Group (2009 – 2018) / Neuroscience Board of the German Research Foundation (DFG) (2009 – 2020) / Delegate of the German Society of Neurology at the World Federation of Neurology (2014 – now) / Deputy Chair and Chair Neurowissenschaftliche Gesellschaft (German Society of Neuroscience) (2017 – 2021) / Chair Scientific Advisory Board Thierry Latran Foundation (2017 – now) / Speaker, Site Ulm of the DZNE (Deutsches Zentrum für Neurodegenerative Erkrankungen) (2018 – now)


Recent papers related to proposal

  • Dorst J, Doenz J, et al. Ludolph AC. Fat-rich versus carbohydrate-rich nutrition in ALS: a randomised controlled study. J Neurol Neurosurg Psychatry. 2022 Mar;93(3):298-302.

  • Hörner R, Kassubek J, et al. Ludolph AC. The spectrum and differential diagnosis of acquired ocular motor nerve palsies: a clinical study of 502 patients. J Neurol. 2022 Apr;269(4):2140-2148.

  • Kandler K, Witzel S, et al. Ludolph AC. ALS Registry Study Group. Phenotyping of the thoracic-onset variant of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2022 May;93(5):563-565.

  • Ludolph AC, Dorst J, et al., LIPCAL-ALS Study Group, Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Ann Neurol. 2020 Feb;87(2):206-216.

  • Ludolph AC, Emilian S, et al., Pattern of Paresis in ALS is Consistent with the Physiology of the Corticomotoneuronal Projections to Different Muscle Groups. JNNP 2020, 10.1136/jnnp-2020-323331.

  • Hagenacker T, Wurster CD, et al. Ludolph AC. Nusinersen in adults with 5q spinal muscular atrophy: a non- interventional, multicentre, observational cohort study. Lancet Neurol. 2020 Apr;19(4):317-325.

  • Miller T, Cudkowicz M, et al. Ludolph AC. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. ALS New England Journal 2020;383(2):109-119.

  • Ludolph AC, Joachim Schuster, et al., RAS-ALS Study Group. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo- controlled, phase 2 trial. Lancet Neurol 2018;17(8):681-688.

  • Fradette S; VALOR and OLE Working Group. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Ned. 2022 Sep 22;387(12):1099-1110.

  • Witzel S, Maier A, et al. Ludolph AC. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of patients with Amyotrophic Lateral Sclerosis. JAMA Neurol. 2022 Jan10:e214893.